bioAffinity Technologies(BIAF) - 2023 Q4 - Annual Results

1 bioAffinity Technologies Reports Fourth Quarter and Full Year 2023 Financial Results ● Reported fiscal year 2023 revenue of $2.5 million, a significant increase from $5,000 in 2022, driven by the September 2023 acquisition of Precision Pathology Laboratory Services (PPLS) and increasing sales of CyPath Lung, the Company's noninvasive test to detect early-stage lung cancer. ● Achieved a milestone with the Centers for Medicare and Medicaid Services (CMS) final determination for payment for CyPath Lung for t ...